Skip to main content
27/10/2022

VHIR researcher Alba Parra, recognized by the European Society of Immunodeficiency Diseases

Alba-Parra-ESID-Young-Talent Awards

27/10/2022

The PhD student of the research group Infection in the immunocompromised pediatric patient has received one of the Junior Talent Awards given by the organization.

The predoctoral researcher of the Infection in the immunocompromised pediatric patient group at Vall d'Hebron Research Institute (VHIR), Alba Parra, has been awarded with the Junior Talent Award of the European Society for Immunodeficiency Diseases (ESID). The award distinguishes three young scientists who stand out for the innovation and impact of their research projects, the winners are chosen among all ESID grant awardees of the last three years.

The three selected scientists were able to present their research during the ESID congress. In the case of the VHIR researcher, she presented the projects that she has managed to continue thanks to the ESID Bridge Grant awarded by the society in 2021. All of them related to rare diseases called inborn errors of immunity (IEI). The most outstanding project has been the development of several laboratory tests to analyze in depth the most complex cases of IEI, i.e. patients with inconclusive genetic diagnosis or patients with genetic variants whose role in the pathology is unknown. During the oral presentation of the awards, the researcher also presented all the scientific publications, collaborations with other research groups and presentations at national and international congresses that she has carried out as a result of her research, which has helped her to contribute to the knowledge of these pathologies.

Alba also spoke about the funding she secured from CSL Behring, a pharmaceutical company specializing in biotechnology and focused on developing therapies for the treatment of rare diseases, to pursue her doctoral project. Her thesis will focus on analyzing the recovery of the humoral immune response in pediatric patients with an IEI who have received a stem cell transplant.
 

Related news

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.

Related professionals

Alba Parra Martínez

Alba Parra Martínez

Research technician
Infection and immunity in pediatric patients
Read more
Rello Saltor, Victoria

Rello Saltor, Victoria

Research technician
Infection and immunity in pediatric patients
Read more
Roig Soria, Laura

Roig Soria, Laura

Predoctoral researcher
Infection and immunity in pediatric patients
Read more
Giménez Sanz, Noemí

Giménez Sanz, Noemí

Infection and immunity in pediatric patients
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.